Tools for Accelerating R&D for Historically Understudied Protein Kinases

加速 R 的工具

基本信息

  • 批准号:
    9264156
  • 负责人:
  • 金额:
    $ 70.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-02-01 至 2019-01-31
  • 项目状态:
    已结题

项目摘要

Protein kinases are central players in almost every aspect of human physiology and serve as critical mediators of signal transduction. The dysfunction of many kinases is implicated in cancer, diabetes, inflammation, and cardiovascular diseases and many are validated targets for therapeutic intervention. The human genome encodes ~518 protein kinases. Yet, the 25 or so marketed protein kinase drugs, target only a small fraction of the human kinome. A greater portion remains unexplored, with very little information available on their role in cell signaling. Chemical tools can play a pivotal role in target discovery and validation. Selective and potent small-molecule kinase inhibitors can be used to address this knowledge gap by pharmacological knockdown of a target protein-kinase in their native environment and probe the effect of inhibition on cell signaling and disease pathology. Our goal is to systematically focus on the vast number of historically understudied kinases, which are currently non-druggable due to lack of mechanistic and functional understanding due to a paucity of reagents and associated assays to gauge selectivity, This gap will be addressed by high-quality chemical probe development, capable of selectively interrogating function of target kinases. During the Phase II period, we will iteratively a) develop low-cost, robust assays using our platform split-luciferase technology for the understudied kinases and, b) develop high- quality chemical probes, which can help deconvolute kinase biology and target discovery. The chemical probe sets developed under this grant will be available as a resource to the research community.
蛋白激酶在人类生理学的几乎每个方面都是中心角色, 信号转导的关键介质。许多激酶的功能障碍与 癌症、糖尿病、炎症和心血管疾病,许多都是经验证的靶点, 治疗干预人类基因组编码约518种蛋白激酶。然而,25个左右的 市售的蛋白激酶药物仅靶向人激酶组的一小部分。更大 部分仍然未被探索,关于它们在细胞信号传导中的作用的信息非常少。 化学工具可以在目标发现和验证中发挥关键作用。选择性和有效 小分子激酶抑制剂可用于通过药理学方法解决这一知识缺口, 在其天然环境中敲低靶蛋白激酶,并探测 抑制细胞信号传导和疾病病理学。 我们的目标是系统地关注大量历史上研究不足的激酶, 由于缺乏对机械和功能的理解, 缺乏试剂和相关的测定来衡量选择性,这一差距将得到解决 通过高质量的化学探针开发,能够选择性地询问功能, 靶激酶。在第二阶段期间,我们将反复a)开发低成本、稳健的检测方法 使用我们的平台分裂荧光素酶技术用于未充分研究的激酶,并且,B)开发高- 高质量的化学探针,可以帮助解卷积激酶生物学和目标发现。的 在此资助下开发的化学探针组将作为研究的资源 社区

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

REENA ZUTSHI其他文献

REENA ZUTSHI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('REENA ZUTSHI', 18)}}的其他基金

Split-luciferase Epigenetic Assays for Drug Discovery
用于药物发现的分裂荧光素酶表观遗传学分析
  • 批准号:
    10482555
  • 财政年份:
    2022
  • 资助金额:
    $ 70.86万
  • 项目类别:
Enabling Toxoplasma gondii Kinome Directed Drug Discovery
实现弓形虫激酶组定向药物发现
  • 批准号:
    10602259
  • 财政年份:
    2019
  • 资助金额:
    $ 70.86万
  • 项目类别:
Kinase Targeted Antimalarial Agents
激酶靶向抗疟药
  • 批准号:
    9918203
  • 财政年份:
    2019
  • 资助金额:
    $ 70.86万
  • 项目类别:
Enabling Malarial Kinome Directed Drug Discovery
实现疟疾激酶组定向药物发现
  • 批准号:
    8714538
  • 财政年份:
    2014
  • 资助金额:
    $ 70.86万
  • 项目类别:
Kinome-wide Cell-Based Assays
全激酶组细胞检测
  • 批准号:
    9205516
  • 财政年份:
    2014
  • 资助金额:
    $ 70.86万
  • 项目类别:
Kinome-wide cell-based assays
全激酶组细胞分析
  • 批准号:
    8780886
  • 财政年份:
    2014
  • 资助金额:
    $ 70.86万
  • 项目类别:
Kinome-wide Cell-Based Assays
全激酶组细胞检测
  • 批准号:
    9053369
  • 财政年份:
    2014
  • 资助金额:
    $ 70.86万
  • 项目类别:
A Poly(ADP-Ribose) Detection Assay Enabling Drug Discovery and Development
聚 (ADP-核糖) 检测分析促进药物发现和开发
  • 批准号:
    8123053
  • 财政年份:
    2011
  • 资助金额:
    $ 70.86万
  • 项目类别:
Rapid Kinase Profiling with Luminescent Reporters
使用发光报告基因快速分析激酶
  • 批准号:
    8005176
  • 财政年份:
    2010
  • 资助金额:
    $ 70.86万
  • 项目类别:
Rapid Kinase Profiling with Luminescent Reporters
使用发光报告基因快速分析激酶
  • 批准号:
    7745380
  • 财政年份:
    2009
  • 资助金额:
    $ 70.86万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 70.86万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.86万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 70.86万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.86万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 70.86万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.86万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 70.86万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 70.86万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 70.86万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.86万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了